Press releases

Intrasense presence at ECR (European Congress of Radiology) from February 26 to March 2, 2025 in Vienna

3 February 2025

Montpellier, France, February 3, 2025. Intrasense (ISIN: FR0011179886 – Mnémo : ALINS), French expert in medical imaging solutions enhanced by AI assisting and securing diagnosis, decision-making and therapeutic follow-up, announces its participation in the European Congress of Radiology (ECR) 2025, which will take place between February 26 and March 2 in Vienna (Austria).

See the press release

Financial calendar 2025

27 January 2025

Intrasense (ISIN: FR0011179886), French expert in medical imaging solutions to assist and secure diagnosis, decision-making and therapeutic follow-up, announces the publication of its financial calendar for fiscal year 2025.

See the press release

Intrasense announces the CE marking of Liflow®’s new version enhanced by AI dedicated to the liver

16 December 2024

Intrasense (FR0011179886 - ALINS), medical imaging software solutions expert and developer of Myrian® et Liflow®, is proud to announce that the Lilfow® solution obtained the CE certification under MDR1, integrating a new AI algorithm for the detection of focal liver lesions developed in collaboration with Guerbet (trade name: DUOnco™ Liver). This new version is being deployed on clinical sites.

See the press release

Guerbet, Intrasense, Gustave Roussy and the University Hospital of Angers receive a €5.9M financing from Bpifrance for Liflow®, innovative solution dedicated to oncology imaging

3 December 2024

Guerbet (FR0000032526 GBT) worldwide expert in contrast agents and medical imaging solutions, Intrasense (FR0011179886 - ALINS), expert in medical imaging software solutions and developer of Myrian® and Liflow®, Gustave Roussy, 1st cancerology centre in France and Europe and Angers University Hospital (« Partners ») announce they have received €5.9M in funding from Bpifrance’s “Innovation in Medical Imaging” call for proposals. The Oncology Assistant (trade name: Liflow®) project, carried by the four Partners uses AI (artificial intelligence) to facilitate and optimize the follow-up of cancer patients. It benefits from public funding to ensure its future development.

See the press release

Intrasense announces the CE marking of Myrian 2.13, enriched by the new version of Guerbet’s prostate AI

20 November 2024

Intrasense (FR0011179886 - ALINS), medical imaging software expert and developer of Myrian® and Liflow®, is proud to announce that the Myrian® 2.13 platform has obtained the CE marking under MDR1, including a major new version of the prostate AI developed by Guerbet, Veolity® LungCAD AI developed by MeVis Medical Solutions AG and Icobrain™ AI developed by Icometrix.

See the press release

Intrasense announces its participation in RSNA 2024, the world's leading medical imaging congress

6 November 2024

Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and developer of Myrian® and Liflow®, announces its participation in the RSNA 2024 international imaging congress. Intrasense will be showcasing its new Liflow® solution, as well as the innovations of the new version of Myrian®, on the stand of its partner Guerbet, symbolizing a collaboration serving excellence in medical imaging at a global level.

See the press release

Liflow®, a solution dedicated to oncology imaging, wins the JFR 2024 Innovation Prize in the “Healthcare IT and AI” category

30 September 2024

Intrasense (FR0011179886 - ALINS), a specialist in medical imaging software solutions and the developer of Myrian® and Liflow®, is proud to announce that its Liflow® solution has been awarded the Prix Innovation JFR (Journées Francophones de la Radiologie) 2024 in the “Healthcare IT and AI” category.

See the press release

Intrasense announces its half-year results for 2024

25 September 2024

Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and developer of Myrian® et Liflow®, announces its consolidated IFRS half-year results for 2024.

See the press release

Guerbet and Intrasense announce the CE marking of DUOnco™ Liver, an artificial intelligence algorithm designed to detect focal liver lesions

23 September 2024

Guerbet (FR0000032526 GBT), worldwide leader in medical imaging, and Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and developer of Myrian® and Liflow®, announce the CE marking under MDR of the liver AI developed by Guerbet (trading name: DUOnco™ Liver).

See the press release

Intrasense attends the « Journées Francophones de Radiologie » 2024

9 September 2024

Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and Myrian® and Liflow® developer, announces its attendance in Journées Francophones de Radiologie (JFR) 2024, where will be presented for the first time the new solution Liflow® as well as the innovations of the new version of Myrian®.

See the press release
1 2 3 12
Subscribe